111 related articles for article (PubMed ID: 2332771)
61. Immunologic and functional features of the leukemic cell of hairy cell leukemia: evidence for a Null hypothesis.
deShazo D; Norris DA; Morris RJ; Bourg W; Johnston RB
Am J Med Sci; 1980; 279(3):135-9. PubMed ID: 7424959
[TBL] [Abstract][Full Text] [Related]
62. The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease.
Harris J; Sengar D; Stewart T; Hyslop D
Cancer; 1976 Feb; 37(2 Suppl):1058-69. PubMed ID: 766953
[TBL] [Abstract][Full Text] [Related]
63. Host defense deficiency in hairy cell leukemia and its correction by leukocyte transfusion.
Hersh EM; Murphy S; Zander A; Dicke K; Stewart DJ; Toki H; Latreille J
Blood; 1980 Sep; 56(3):526-33. PubMed ID: 7407417
[TBL] [Abstract][Full Text] [Related]
64. Hemolytic-uremic syndrome due to deoxycoformycin: a report of the second case.
Sakai C; Takagi T; Wakatsuki S; Matsuzaki O
Intern Med; 1995 Jun; 34(6):593-6. PubMed ID: 7549151
[TBL] [Abstract][Full Text] [Related]
65. Peri-operative changes of cellular and humoral components of immunity with brain tumour surgery.
Dauch WA; Krex D; Heymanns J; Zeithammer B; Bauer BL
Acta Neurochir (Wien); 1994; 126(2-4):93-101. PubMed ID: 8042561
[TBL] [Abstract][Full Text] [Related]
66. Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets.
Tenser RB; Hay KA; Aberg JA
Arch Neurol; 1993 Apr; 50(4):417-20. PubMed ID: 8460964
[TBL] [Abstract][Full Text] [Related]
67. Clinical significance of natural killer cell cytotoxicity: need for proper data analysis in the design of clinical studies.
Rusthoven JJ
Eur J Cancer Clin Oncol; 1985 Nov; 21(11):1287-93. PubMed ID: 3908119
[No Abstract] [Full Text] [Related]
68. Generalized monocyte deficiency in leukaemic reticuloendotheliosis.
Janckila AJ; Wallace JH; Yam LT
Scand J Haematol; 1982 Aug; 29(2):153-60. PubMed ID: 6753123
[TBL] [Abstract][Full Text] [Related]
69. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.
Ragon BK; Mehta RS; Gulbis AM; Saliba RM; Chen J; Rondon G; Popat UR; Nieto Y; Oran B; Olson AL; Patel K; Hosing CM; Qazilbash MH; Shah N; Kebriaei P; Shpall EJ; Champlin RE; Alousi AM
Bone Marrow Transplant; 2018 Mar; 53(3):315-325. PubMed ID: 29269797
[TBL] [Abstract][Full Text] [Related]
70. Hairy cell leukemia - immunotargets and therapies.
Basheer F; Bloxham DM; Scott MA; Follows GA
Immunotargets Ther; 2014; 3():107-20. PubMed ID: 27471703
[TBL] [Abstract][Full Text] [Related]
71. Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation.
Gatza E; Choi SW
Int J Hematol Oncol; 2015 Aug; 4(3):113-126. PubMed ID: 27182433
[TBL] [Abstract][Full Text] [Related]
72. Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
Maurer C; Langerbeins P; Bahlo J; Cramer P; Fink AM; Pflug N; Engelke A; von Tresckow J; Kovacs G; Stilgenbauer S; Wendtner CM; Müller L; Ritgen M; Seiler T; Fischer K; Hallek M; Eichhorst B
Leukemia; 2016 Oct; 30(10):2019-2025. PubMed ID: 27133817
[TBL] [Abstract][Full Text] [Related]
73. Inhibition of adenosine deaminase (ADA)-mediated metabolism of cordycepin by natural substances.
Li G; Nakagome I; Hirono S; Itoh T; Fujiwara R
Pharmacol Res Perspect; 2015 Mar; 3(2):e00121. PubMed ID: 26038697
[TBL] [Abstract][Full Text] [Related]
74. Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective.
Andritsos LA; Dunavin N; Lozanski G; Jones JA; Blachly JS; Lucas DM; Byrd JC; Kraut E; Grever MR
Haematologica; 2015 Jan; 100(1):e18-20. PubMed ID: 25361945
[No Abstract] [Full Text] [Related]
75. Current and emerging strategies for the prevention of graft-versus-host disease.
Choi SW; Reddy P
Nat Rev Clin Oncol; 2014 Sep; 11(9):536-47. PubMed ID: 24958183
[TBL] [Abstract][Full Text] [Related]
76. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.
Poi MJ; Hofmeister CC; Johnston JS; Edwards RB; Jansak BS; Lucas DM; Farag SS; Dalton JT; Devine SM; Grever MR; Phelps MA
Clin Pharmacokinet; 2013 Aug; 52(8):705-12. PubMed ID: 23588536
[TBL] [Abstract][Full Text] [Related]
77. How I treat hairy cell leukemia.
Grever MR
Blood; 2010 Jan; 115(1):21-8. PubMed ID: 19843881
[TBL] [Abstract][Full Text] [Related]
78. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia.
Wendelbo Ø; Nesthus I; Sjo M; Paulsen K; Ernst P; Bruserud Ø
Cancer Immunol Immunother; 2004 Aug; 53(8):740-7. PubMed ID: 15133630
[TBL] [Abstract][Full Text] [Related]
79. Drug-induced lymphopenia: focus on CD4+ and CD8+ cells.
Gergely P
Drug Saf; 1999 Aug; 21(2):91-100. PubMed ID: 10456378
[TBL] [Abstract][Full Text] [Related]
80. Non-Hodgkin's lymphoma in the elderly: a guide to drug treatment.
Niitsu N
Drugs Aging; 1999 Jun; 14(6):447-57. PubMed ID: 10408743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
